Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/056180external-prioritypatent/WO2011060035A1/en
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Publication of TN2012000207A1publicationCriticalpatent/TN2012000207A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
As ORL-1 receptor antagonist of the formula I, its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful; in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraine.
TNP2012000207A2010-01-272012-05-08Spiropiperidine compounds as orl-1 receptor antagonists
TN2012000207A1
(en)
Spiropiperidine derived compounds; pharmaceutical composition; and use as orl-1 receptor antagonists in the treatment of depression, migraine, obesity.